1. Home
  2. QTRX vs ANL Comparison

QTRX vs ANL Comparison

Compare QTRX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanterix Corporation

QTRX

Quanterix Corporation

HOLD

Current Price

$3.92

Market Cap

306.0M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$7.07

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QTRX
ANL
Founded
2007
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
293.4M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
QTRX
ANL
Price
$3.92
$7.07
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$11.33
$16.00
AVG Volume (30 Days)
683.1K
185.4K
Earning Date
03-02-2026
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,632,000.00
N/A
Revenue This Year
$25.49
N/A
Revenue Next Year
$9.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
64.52
N/A
52 Week Low
$3.64
$0.88
52 Week High
$8.77
$12.09

Technical Indicators

Market Signals
Indicator
QTRX
ANL
Relative Strength Index (RSI) 24.33 40.32
Support Level N/A $1.36
Resistance Level $6.27 $9.98
Average True Range (ATR) 0.29 0.77
MACD -0.09 -0.27
Stochastic Oscillator 18.55 16.36

Price Performance

Historical Comparison
QTRX
ANL

About QTRX Quanterix Corporation

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: